Recent 8-K filings for EQ
Highest-materiality recent filing
Equillium announces FDA declined Breakthrough Therapy and Accelerated Approval for itolizumab in aGVHD
- FDA declined Breakthrough Therapy designation and Accelerated Approval for itolizumab in aGVHD based on EQUATOR study data.
- FDA focused on Day 29 outcomes; itolizumab did not show improvement by Day 29 despite favorable safety and longer-term data.
-
Equillium stockholders approve reverse stock split and authorized share increase at annual meeting
Reverse stock split approved at ratio of 1-for-2 to 1-for-20, with timing and ratio at Board's discretion.
-
Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026
Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.
-
Equillium Q4 2025 revenue $0, net loss $3.8M; cash runway into 2029 after $35M financing
Q4 2025 revenue $0 (vs $4.4M Q4 2024); FY2025 revenue $0 (vs $41.1M FY2024 from Ono deal).
-
Equillium raises ~$35M in private placement with RA Capital to fund EQ504
Issued 1,179,508 shares at $1.854/share and pre-funded warrant for up to 17,698,593 shares at $0.0001 exercise price.
-
Equillium reports Q3 net loss of $4.2M; announces $50M financing and EQ504 Phase 1 plan for mid-2026
Q3 2025 revenue $0 vs $12.2M in prior year; net loss $4.2M ($0.06 per share) vs $7,000 loss in Q3 2024.
-
Equillium confirms Crowe LLP as auditor for FY2025, effective Oct 21, 2025
Engagement letter with Crowe LLP executed Oct 21, 2025; client acceptance procedures completed same day.
-
Equillium ends Biocon itolizumab deal, dismisses KPMG, two directors resign
Terminated collaboration with Biocon; all itolizumab licenses reverted. Technical service fee of $363k set-off against amounts owed.
-
Equillium ups ATM facility to $75M from $21.95M; prior sales $0.96M
Filed prospectus supplement to increase aggregate offering price of common stock under existing Sales Agreement to $75M.
-
Equillium regains Nasdaq minimum bid price compliance
Nasdaq notified Equillium on Aug 29, 2025 that it has regained compliance with the $1.00 minimum bid price rule.
-
Equillium raises $30M in private placement; cash runway through 2027
Initial closing of 21.8M shares at $0.57/sh and pre-funded warrants for 30.8M shares, gross proceeds $30M.
-
Equillium adopts crypto treasury strategy; cash $11.5M, runway into Q4 2025; going concern doubt
Cash and cash equivalents $11.5M as of June 30, 2025; expects to fund operations into Q4 2025.
-
Equillium receives Nasdaq extension to Dec 8, 2025 for bid price compliance
Nasdaq granted Equillium (EQ) until Dec 8, 2025 to regain minimum $1.00 bid price compliance.
-
Equillium stockholders approve reverse stock split and equity plan amendment
Stockholders authorized reverse stock split at ratio 1:2 to 1:20, with board discretion on timing and ratio.
-
FDA declined Breakthrough Therapy designation and Accelerated Approval for itolizumab in aGVHD based on EQUATOR study data.
-
Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates
Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).
-
Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo
Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.
-
Equillium receives Nasdaq minimum bid price non-compliance notice; cure period until June 11, 2025
Nasdaq notified Equillium on Dec 13, 2024 that common stock bid price was below $1.00 for 30 consecutive business days.
-
Equillium director Yu Xu resigns; Peter Colabuono appointed to board
Yu (Katherine) Xu, Ph.D., resigned from Equillium board and audit committee effective Dec 10, 2024; no disagreement cited.
-
Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination
Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.
-
Equillium regains Nasdaq minimum bid price compliance after meeting $1.00 close for 10 days
Received Nasdaq notice on Oct 30, 2024 confirming compliance regained as of Oct 29, 2024.
-
Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.
-
Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024
Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.
-
Equillium receives Nasdaq bid price deficiency notice; cure deadline Jan 15, 2025
Received Nasdaq notice on July 19, 2024 for bid price below $1.00 for 30 consecutive business days.
-
Equillium estimates cash balance of $33.3M as of June 30, 2024
Preliminary cash, cash equivalents and short-term investments approximately $33.3 million as of June 30, 2024.
-
Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.
-
Equillium stockholders approve reverse stock split amendment at annual meeting
Approved amendment to certificate of incorporation for reverse stock split at ratio of 1:2 to 1:10, with board discretion on timing and ratio.
-
Equillium Q1 revenue $10.7M, net loss $2.7M; positive lupus data, milestones ahead
Revenue of $10.7M, up from $8.9M YoY, all from Ono partnership (development funding and amortization).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event other_material